Document:

Exhibit 4.63

 

 

 

 

Cabot Brown

 

 

 

10th April 2017

 

Dear Cabot, 

 

Fee Increase

 

I am pleased
to confirm that with effect from the 1st January 2017 your fees have been increased to $90,000 per annum.

 

All other
terms and conditions of your appointment remain unchanged.

 

If you have any questions please do not hesitate to contact me.

 

Yours Sincerely

 

Adam George

Company Secretary

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GW Pharmaceuticals plc
Sovereign House, Vision Park, Histon, Cambridge, CB24 9BZ

Telephone : +44 (0)1223 266800       www.gwpharm.comExhibit 4.64

 

 

 

James Noble

 

10th April 2017

 

Dear James,

 

Fee increase

 

I am pleased to confirm that with effect from
the 1st January 2017 your fees have been increased to $92,000 per annum.

 

All other terms and conditions of your appointment remain unchanged.

 

If you have any questions please do not hesitate to contact me.

 

	Yours Sincerely	 
	 	 
	/s/ Adam George	 
	Adam George	 
	Company Secretary	 

 

GW Pharmaceuticals plc Sovereign House, Vision
Park, Histon, Cambridge, CB24 9BZ

Telephone: +44 (0)1223 266800 www.gwpharm.comExhibit 4.65

 

 

 

FILE NOTE

 

Employee – Chris Tovey

 

Date - 13/04/17

 

Base Pay Increase/Bonus and Removal of Allowances

 

Base Pay increase to £273,881 per annum with effect from
1/1/17.

 

Annual Bonus of £215,234 for 2016 paid with February 2017's
pay.

 

GW Pension Contributions and Car Allowance
have been aggregated in to 2017 base pay.

 

	/s/
    Philippa Crompton	 
	Philippa Crompton, HR Director	 
	 	 
	Date - 13/04/17	 

 

GW Pharmaceuticals plc Sovereign House Histon
Cambridge United Kingdom

Telephone: +44 (0)1223 266800 Facsimile: +44
(0)1223 235667 www.gwpharm.com

Company No. 4160917
Registered in England and WalesExhibit 4.66

 

 

 

FILE NOTE

 

Employee – Geoffrey Guy

 

Date - 13/04/17

 

Base Pay Increase/Bonus and Removal of Allowances

 

Base Pay increase to £451,684 per annum with effect from
1/1/17.

 

Annual Bonus of £355,603 for 2016 paid with February 2017's
pay.

 

GW Pension Contributions and Car Allowance
have been aggregated in to 2017 base pay.

 

	/s/
    Philippa Crompton	 
	Philippa Crompton, HR Director	 
	 	 
	Date - 13/04/17	 

 

GW Pharmaceuticals plc Sovereign House Histon
Cambridge United Kingdom

Telephone: +44 (0)1223 266800 Facsimile: +44
(0)1223 235667 www.gwpharm.com

Company No. 4160917
Registered in England and WalesExhibit 4.67 

 

 

 

FILE NOTE

 

Employee – Stephen Wright 

 

Date - 13/04/17

 

Base Pay Increase/Bonus and Removal of Allowances

 

Base Pay increase to £307,877 per annum with effect from
1/1/17.

 

Annual Bonus of £243,564 for 2016 paid with February 2017's
pay.

 

GW Pension Contributions and Car Allowance
have been aggregated in to 2017 base pay.

 

	/s/
    Philippa Crompton	 
	Philippa Crompton, HR Director	 
	 	 
	Date - 13/04/17	 

 

GW Pharmaceuticals plc Sovereign House Histon
Cambridge United Kingdom

Telephone: +44 (0)1223 266800 Facsimile: +44
(0)1223 235667 www.gwpharm.com

Company No. 4160917 Registered in England and
WalesExhibit 4.68

 

 

 

FILE NOTE

 

Employee – Adam George 

 

Date - 13/04/17

 

Base Pay Increase/Bonus and Removal of Allowances

 

Base Pay Increase to £273,881 per annum with effect
from 1/1/17.

 

Annual Bonus of £198,248 for 2016 paid with February
2017's pay.

 

GW Pension Contributions and Car Allowance
have been aggregated in to 2017 base pay.

 

	/s/
    Philippa Crompton	 
	Philippa Crompton, HR Director	 
	 	 
	Date - 13/04/17	 

 

GW Pharmaceuticals plc Sovereign
House Histon Cambridge United Kingdom

Telephone: +44 (0)1223 266800 Facsimile: +44 (0)1223 235667 www.gwpharm.com

Company No. 4160917
Registered in England and WalesExhibit 4.69

 

 

PRIVATE & CONFIDENTIAL

COMPENSATION MEMO

 

	Date:	February 21, 2017	 
	To:	Justin Gover	 
	From: 	Tom Lynch	 
	cc:	Human Resources	 

 

**************************************************************************************

 

Justin,

 

I am pleased to inform you of the following compensation decisions,
approved by the Remuneration Committee:

 

	 	Annual Salary - Effective January 1, 2017
	 	New Base Salary:	540,000 USD
	 	 	 
	 	Paid via US Payroll:	487,488 USD
	 	Paid via UK Payroll:	  52,512 USD
	 	 	 
	 	Please note that effective
January 1, 2017, the company provided pension contribution of 17.5% of your salary and your car allowance of $24,279 per annum
have ceased.

 

	 	Performance Bonus -  Discretionary bonus to be paid Mar 3, 2017
	 	Bonus Amount: 	455,100 USD

 

	 	Long Term Incentive Plan (LTIP) – Grant date January 6, 2017
	 	Restricted Stock Options:	  70,068  UK Ordinary Shares
	 	Performance Stock Options:	233,568  UK Ordinary Shares
	 	Market Priced Options:	142,344  UK Ordinary Shares

 

Thank you for all of your hard work. I
look forward to us working together to achieve yet more this year.Exhibit 4.70

 

 

 

PRIVATE & CONFIDENTIAL

COMPENSATION MEMO

 

	Date:	February 22, 2017	 
	To:	Julian Gangolli	 
	From: 	Justin Gover	 
	cc:	Human Resources	 

 

**************************************************************************************

 

Julian,

 

I am pleased to inform you of the following compensation decisions,
approved by the Remuneration Committee:

 

	 	Annual Salary - Effective January 1, 2017
	 	Current Salary:	408,000 USD
	 	New Base Salary:	420,240 USD
	 	% Increase:	3.00%

 

Note: Effective Feb 1, 2017 all of your salary
will be paid through the US payroll.

 

	 	Performance Bonus - Discretionary bonus to be paid Mar 3, 2017
	 	Bonus Amount:	408,000 USD
	 	 	 
	 	Long Term Incentive Plan (LTIP) – Grant date January 6, 2017
	 	Restricted Stock Options:	  43,152  UK Ordinary Shares
	 	Performance Stock Options:	143,832  UK Ordinary Shares
	 	Market Priced Options:	  87,660  UK Ordinary Shares

 

Thank you for all of your hard work. I look forward to us working
together to achieve yet more this year.Exhibit 4.71

 

 

 

Your offer.

February 20, 2017

 

Scott Giacobello

 

Dear Scott:

 

Greenwich Biosciences, Inc. is pleased to offer you the position
of Chief Financial Officer for GW Pharmaceuticals, based in Carlsbad, CA. In this position, you will report directly to Justin
Gover, Chief Executive Officer of GW Pharmaceuticals. Your anticipated start date will be March 6, 2017.

 

Base Compensation

In this exempt position, your salary will be $375,000 annualized,
less applicable taxes and other withholdings, and paid bi-weekly in accordance with Greenwich Biosciences’ normal payroll
practices.

 

Bonus Plan 

You will be eligible to participate in Greenwich Biosciences’
discretionary Bonus Plan per standard company practices with a bonus target of 50% of base pay. Any bonus earned will be based
on a combination of the Company’s overall performance, financial position, and individual performance, to be determined by
the Remuneration Committee in its sole discretion. Any bonus earned will be in accordance of the terms and conditions of the plan,
which states in part you must be employed on the day the bonus is paid to earn and receive the bonus. Any bonus will be pro-rated
for the year of hire.

 

Long Term Incentive Plan (LTIP)

If you decide to join and subject to ratification from the Remuneration
Committee, within three months following the start of your employment with Greenwich Biosciences, you will be granted LTIP share
options with a targeted economic grant value of $1,125,000 through three instruments and subject to your continuous employment
with Greenwich Biosciences:

 

		·	25% as Market Priced Options that vest on the third anniversary of
the date of grant

		·	25% as Restricted Stock Options that vest in annual 1/4th
equal increments over a four year period 

		·	50% as Performance Stock Options that vest on the third anniversary
of the date of grant subject to the following corporate performance conditions having been achieved:

		o	50% of the Performance Stock Options will vest upon receipt from FDA of their confirmation of acceptance of an Epidiolex NDA
filing

		o	50% of the Performance Stock Options will vest upon FDA grant of Epidiolex regulatory approval

 

The share options will be subject to the terms of the LTIP and grant
documents thereunder which will be provided to you evidencing the specifics of your grant.

 

Greenwich Biosciences, Inc.
5800 Armada Drive, Suite 210, Carlsbad, CA 92008

 

     

     

    

 

Change in Control and Severance Benefit Plan (CIC Plan)

If you decide to join and subject to approval of the Greenwich Biosciences’
Change in Control and Severance Benefit Plan (CIC Plan) by the Remuneration Committee, you will be a participant in the CIC Plan.
Under the CIC Plan, you will be eligible to receive vesting acceleration of your LTIP share options describe above upon certain
change in control events involving Greenwich Biosciences and/or GW Pharmaceuticals plc. You will also be eligible to receive additional
severance benefits under the CIC Plan which will be set forth in a participation agreement provided to you. After you join, you
will be provided a copy of the CIC Plan and your individual participation agreement containing the details of these benefits and
you will be required to execute and return the participation agreement to us.

 

To indicate your acknowledgement of the terms of your employment,
please sign, date and return to me by February 21, 2017.

 

We look forward to your favorable reply and having you join the
Greenwich Biosciences team.

 

	 	Sincerely,
	 	 
	 	/s/ Shelly Applegate
	 	 
	 	Shelly Applegate
	 	Vice President, Human Resources

 

Scott Giacobello

 

	/s/  Scott Giacobello	 	2/21/17 
	Signature	 	Date

 

Greenwich Biosciences, Inc.
5800 Armada Drive, Suite 210, Carlsbad, CA 92008

 

     

     

    

 

Your benefits.

 

Time Off

Greenwich Biosciences currently offers Chief/President Level employees
20 days per year of paid vacation, which begins to accrue upon the date you commence work with the Company. You will also be eligible
to take a maximum of 8 paid sick days for illness or injury per calendar year, which may also be used for the illness or injury
of family members and for certain other purposes in accordance with applicable laws. Based on your hire date, you are eligible
to take a maximum of 8 paid sick days in 2017. In addition, Greenwich Biosciences provides 11 paid holidays per year, consisting
of 9 company designated holidays and 2 personally designated floating holidays.

 

Retirement Savings Plan

Greenwich Biosciences offers a 401(k) and employees may elect to
contribute an amount of up to 100% (in whole percentages and subject to limits prescribed by law) of eligible compensation each
payroll period. Employees are also permitted to make post-tax Roth contributions (subject to legal requirements). Greenwich Biosciences
will match 50% of the first 6% you contribute per pay period.

 

Health Benefits

Full-time employees are eligible for company sponsored benefits
(medical, dental, vision) on the first day of the month following first day of employment.

 

Other Insurance

Greenwich Biosciences pays 100% of the monthly premium for employees
to be covered under Basic Life and AD&D Insurance at 2x annual base salary up to a maximum of $500,000. In addition, Greenwich
Biosciences provides Short and Long Term Disability benefits.

 

Flexible Spending Accounts

You have the option to enroll in and contribute towards an FSA helping
to reduce your taxable income and pay for eligible expenses for yourself, your spouse, and your eligible dependents, on a tax-free
basis.

 

Other

These are descriptions of discretionary benefits currently provided
to US employees. All compensation, benefits and employer policies and programs will be administered in accordance with Greenwich
Biosciences’ policies, plans and procedures, which may include waiting periods and other eligibility requirement to participate.
Greenwich Biosciences reserves the right to change or eliminate these policies and programs at any time during the course of your
employment, without notice or compensation. Provision of any benefits listed in this section is discretionary and is not considered
part of your employment offer. Please sign and date here to confirm that you have read and understand this document:

 

Scott Giacobello

 

	/s/  Scott Giacobello	 	2/21/17 
	Signature	 	Date

 

Greenwich Biosciences, Inc.
5800 Armada Drive, Suite 210, Carlsbad, CA 92008

 

     

     

    

 

Almost there.

 

Congratulations on your offer of employment with Greenwich
Biosciences! This offer is contingent upon the following:

 

		1.	Successful completion of a background check.

 

		2.	Compliance with federal I-9 requirements (please bring documentation on your first day of work verifying your identity and
legal authorization to work in the United States).

 

		3.	Signing and complying with Greenwich Biosciences’ Confidential Information and Invention Assignment Agreement, which
requires, among other provisions, the assignment of patent rights to any invention made during your employment at Greenwich Biosciences.

 

		4.	Signing and complying with Greenwich Biosciences’ Arbitration Agreement.

 

		5.	Your representation that working for Greenwich Biosciences will not cause you to violate any contractual or other obligations
you have to any third party, including a former employer.

 

		6.	As a Greenwich Biosciences employee, you will be expected to abide by the Company’s rules and standards. Specifically,
you will be required to sign an acknowledgment that you have read and that you understand the Company’s Code of Conduct,
Insider Trading Policy, Whistleblower Policy, and the Company Handbook.

 

Should you accept our offer, your employment with Greenwich
Biosciences will be “at-will.” This means your employment with Greenwich Biosciences is not for a specific term and
may be terminated by either you or Greenwich Biosciences at any time with or without cause and with or without advance notice.
In addition, Greenwich Biosciences reserves the right to modify your position or duties to meet business needs and to use discretion
in deciding on appropriate discipline.

 

This document, together with the agreements referenced above,
as well as your offer letter, constitutes the entire agreement between you and Greenwich Biosciences relating to the terms and
conditions of your employment and supersedes all prior and contemporaneous agreements, understandings, negotiations or representations,
whether written or oral, express or implied on this subject. This letter may not be modified or amended except by a specific written
agreement signed by you and GW Pharmaceutical’s Chief Executive Officer. Note that base compensation and bonus are subject
to adjustment by the Company, in its sole discretion from time to time.

 

I have read this Offer Contingencies document in its entirety,
along with the referenced documents, and agree to the terms and conditions of employment. I understand and agree that my employment
with Greenwich Biosciences is at-will. By signing below, I represent that I am not restricted from working for Greenwich Biosciences
and that my employment with Greenwich Biosciences will not cause me to violate any obligations I have to any third party, including
a former employer.

 

Scott Giacobello

 

	/s/  Scott Giacobello	 	2/21/17 
	Signature	 	Date

 

Greenwich Biosciences, Inc.
5800 Armada Drive, Suite 210, Carlsbad, CA 92008

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]